EIK1001
EIK1001-005
Phase 2 small_molecule active
Quick answer
EIK1001 for NSCLC is a Phase 2 program (small_molecule) at Eikon Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eikon Therapeutics
- Indication
- NSCLC
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active